HEMATOLOGY

• A Phase I study for Hodgkin’s Lymphoma patients
• A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Weekly Administration of GRN163L in Patients with Chronic Lymphoproliferative Disease

ONCOLOGY

• An Open-Label, Randomized, Phase II Study of Efficacy and Tolerability of a novel Receptor Tyrosine Kinase (RTK) Inhibitor in Advanced or Metastatic Non-Small Cell Lung Cancer. This study is closed to accrual.
• A Multicenter, Open-Label Safety and Pharmacokinetics Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody in Patients with Refractory Advanced Solid Tumor Malignancies.
• A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety and Pharmacokinetics of AZD4877 Administered Weekly in Patients with Recurrent Advanced UrothelialCancer.
• A Single-Blind, Multicenter, Placebo-Controlled, Sequential Design Study Evaluating the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram (with open label extension)
• A Phase 1/2 Study to Investigate the Safety, Tolerability and Potential Activity of IPI-504 in Relapsed and/or Refractory Stage IIIb (with Malignant Pleural or Pericardial Effusion), or Stage IV NSCLC Patients

• Phase I for Multiple Myeloma
• Phase I for Selected Solid Tumors: Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Melanoma, Ovarian Cancer.
• A Phase I/II of an Immunotherapeutic Agent in Solid Tumors